MMP2 and neoplasm: This study analyzed miRNA pathway enrichment derived from tumor-normal mRNA differential expression in esophageal squamous cell carcinoma (ESCC) patients and investigated whether Ilomastat, a known MMP inhibitor, could plausibly bind the catalytic site of MMP-2.